drugset / Trial / NCT06414902

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

NCT06414902

Phase 1 Recruiting 60 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.

Timeline

Start
2024-09-04
Primary completion
2027-10-01
Completion
2027-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ArabinoFuranosylGuanine [18F]F-AraG Diagnostic / imaging agent Intravenous

Indications